» Articles » PMID: 24091729

MiR-29b Induces SOCS-1 Expression by Promoter Demethylation and Negatively Regulates Migration of Multiple Myeloma and Endothelial Cells

Abstract

Epigenetic silencing of tumor suppressor genes frequently occurs and may account for their inactivation in cancer cells. We previously demonstrated that miR-29b is a tumor suppressor microRNA (miRNA) that targets de novo DNA methyltransferases and reduces the global DNA methylation of multiple myeloma (MM) cells. Here, we provide evidence that epigenetic activity of miR-29b leads to promoter demethylation of suppressor of cytokine signaling-1 (SOCS-1), a hypermethylated tumor suppressor gene. Enforced expression of synthetic miR-29b mimics in MM cell lines resulted in SOCS-1 gene promoter demethylation, as assessed by Sequenom MassARRAY EpiTYPER analysis, and SOCS-1 protein upregulation. miR-29b-induced SOCS-1 demethylation was associated with reduced STAT3 phosphorylation and impaired NFκB activity. Downregulation of VEGF-A and IL-8 mRNAs could be detected in MM cells transfected with miR-29b mimics as well as in endothelial (HUVEC) or stromal (HS-5) cells treated with conditioned medium from miR-29b-transfected MM cells. Notably, enforced expression of miR-29b mimics increased adhesion of MM cells to HS-5 and reduced migration of both MM and HUVEC cells. These findings suggest that miR-29b is a negative regulator of either MM or endothelial cell migration. Finally, the proteasome inhibitor bortezomib, which induces the expression of miR-29b, decreased global DNA methylation by a miR-29b-dependent mechanism and induced SOCS-1 promoter demethylation and protein upregulation. In conclusion, our data indicate that miR-29b is endowed with epigenetic activity and mediates previously unknown functions of bortezomib in MM cells.

Citing Articles

Multiple Myeloma: Genetic and Epigenetic Biomarkers with Clinical Potential.

Veryaskina Y, Titov S, Skvortsova N, Kovynev I, Antonenko O, Demakov S Int J Mol Sci. 2025; 25(24.

PMID: 39769169 PMC: 11679576. DOI: 10.3390/ijms252413404.


The multi-faceted roles of cancer-associated fibroblasts in pancreatic cancer.

Kwon J, Vera R, Fernandez-Zapico M Cell Signal. 2025; 127:111584.

PMID: 39756502 PMC: 11807759. DOI: 10.1016/j.cellsig.2024.111584.


Epigenetic Alterations as Vital Aspects of Bortezomib Molecular Action.

Kulig P, Luczkowska K, Bakinowska E, Baumert B, Machalinski B Cancers (Basel). 2024; 16(1).

PMID: 38201512 PMC: 10778101. DOI: 10.3390/cancers16010084.


Lipid metabolic vulnerabilities of multiple myeloma.

Torcasio R, Gallo Cantafio M, Ikeda R, Ganino L, Viglietto G, Amodio N Clin Exp Med. 2023; 23(7):3373-3390.

PMID: 37639069 PMC: 10618328. DOI: 10.1007/s10238-023-01174-2.


Cancer-associated fibroblast-derived exosome microRNA-21 promotes angiogenesis in multiple myeloma.

Miaomiao S, Xiaoqian W, Yuwei S, Chao C, Chenbo Y, Yinghao L Sci Rep. 2023; 13(1):9671.

PMID: 37316504 PMC: 10267152. DOI: 10.1038/s41598-023-36092-6.


References
1.
Miranda T, Jones P . DNA methylation: the nuts and bolts of repression. J Cell Physiol. 2007; 213(2):384-90. DOI: 10.1002/jcp.21224. View

2.
Deaton A, Bird A . CpG islands and the regulation of transcription. Genes Dev. 2011; 25(10):1010-22. PMC: 3093116. DOI: 10.1101/gad.2037511. View

3.
Li A, Dubey S, Varney M, Dave B, Singh R . IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol. 2003; 170(6):3369-76. DOI: 10.4049/jimmunol.170.6.3369. View

4.
Calo V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N . STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol. 2003; 197(2):157-68. DOI: 10.1002/jcp.10364. View

5.
Calimeri T, Battista E, Conforti F, Neri P, Di Martino M, Rossi M . A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia. 2011; 25(4):707-11. PMC: 3089835. DOI: 10.1038/leu.2010.300. View